drugset
drugset / Trial / NCT04586660

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

NCT04586660 ↗

Phase 4 Active not recruiting 36 enrolled Amgen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).

Timeline

Start
2023-08-17
Primary completion
2028-03-07
Completion
2028-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 120 mg Subcutaneous

Indications

bone giant cell tumor